TrialAdvances in therapy2025

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison.

Noemi Puig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.